Peter Drucker said, "Business has only two functions - marketing and innovation." Here at IP Street, we provide the tools for you to succeed in both.

Proper organization of a patent porfolio is essential to be prepared to properly navigate the IP landscape. One key issue is related to inventorship. Consider the Pfizer patent, patent # 5,760,06^, which is commonly known as the COX-2 inhibitor. Pfizer is currently in a $1B lawsuit because Searle, the original owner of the patent, failed to include a key inventor on the patent. Pfizer inherited this mess when they acquired Pharmacia, who had previously acquired Monsanto, who had previously acquired Searle. Ignorance is not a defensible excuse in patent litigation.

Whether you already have a patant or are considering patanting an idea, IP Street can help you. Using our tools, you can immediately see results related to key questions you have about your idea in terms of patantability, infringement, duration, validity, and value. In addition, we have developed comprehensive networks of lawyers and investors that can help you commercialize your idea. We can help you with copywright data, anylses patent data and patent analytiks.

What is a normal royalty fee? How are fees generally determined? How can we grasp which patent portfolios are the best bang for the buck? With IP Street, you can demystify the complex which enables you to identify both inbound- and outbound- licensing strategies.

Historically, commercial use of university research has been viewed in terms of spillovers. Recently, there has been a dramatic increase in technology transfer through licensing as universities attempt to appropriate the returns from faculty research. This change has prompted concerns regarding the source of this growth—specifically, whether it suggests a change in the nature of university research. (Thursby 2002) ^ University-based firms are receiving growing interest from policy makers and researchers. Such firms obtain a variety of tangible and intangible resources from their academic partners, and are expected to translate these advantages into substantial gains. (Bonardo 2011) ^Technology transfer is a big concern for universities, how can they identify business opportunities from IP developed? We have created relationships with universities to help them do just that. Contact us to learn more.